Evidence map›Paper›PMID 33809279›Full record

ArticleInternational journal of molecular sciences2021

Muscle Damage in Systemic Sclerosis and CXCL10: The Potential Therapeutic Role of PDE5 Inhibition.

Clarissa Corinaldesi, Rebecca L Ross, Giuseppina Abignano, Cristina Antinozzi, Francesco Marampon, Luigi di Luigi, Maya H Buch, Valeria Riccieri, Andrea Lenzi, Clara Crescioli and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. The Prostacyclin Analogue Iloprost Modulates CXCL10 in Systemic Sclerosis.International journal of molecular sciences · 2022
    Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Clarissa CorinaldesiLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds LS9 7TF, UK.
Rebecca L RossLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds LS9 7TF, UK.
Giuseppina AbignanoLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds LS9 7TF, UK.
Cristina AntinozziDepartment of Movement, Human and Health Sciences, University of Rome Foro Italico, 00135 Rome, Italy.ORCID 0000-0003-4296-5081
Francesco MaramponDepartment of Movement, Human and Health Sciences, University of Rome Foro Italico, 00135 Rome, Italy.
Luigi di LuigiDepartment of Movement, Human and Health Sciences, University of Rome Foro Italico, 00135 Rome, Italy.
Maya H BuchLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds LS9 7TF, UK.
Valeria RiccieriDepartment of Internal Medicine and Medical Specialties, University Sapienza, 00185 Rome, Italy.
Andrea LenziDepartment of Experimental Medicine, Sapienza University of Rome, 00185 Rome, Italy.
Clara CrescioliDepartment of Movement, Human and Health Sciences, University of Rome Foro Italico, 00135 Rome, Italy.ORCID 0000-0003-3339-3114
Francesco Del GaldoLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds LS9 7TF, UK.
University of Leeds · GBForo Italico University of Rome · ITSapienza University of Rome · IT

Funding

Medical Research Council MC_PC_13066
6 · The paper itself

Abstract

Skeletal muscle damage is a common clinical manifestation of systemic sclerosis (SSc). C-X-C chemokine ligand 10 (CXCL10) is involved in myopathy and cardiomyopathy development and is associated with a more severe SSc prognosis. Interestingly, the phosphodiesterase type 5 inhibitor (PDE5i) sildenafil reduces CXCL10 sera levels of patients with diabetic cardiomyopathy and in cardiomyocytes. Here, we analyzed the levels of CXCL10 in the sera of 116 SSc vs. 35 healthy subjects and explored differences in 17 SSc patients on stable treatment with sildenafil. CXCL10 sera levels were three-fold higher in SSc vs. healthy controls, independent of subset and antibody positivity. Sildenafil treatment was associated with lower CXCL10 sera levels. Serum CXCL10 strongly correlated with the clinical severity of muscle involvement and with creatine kinase (CK) serum concentration, suggesting a potential involvement in muscle damage in SSc.

Indexed as

Chemokine CXCL10Cyclic Nucleotide Phosphodiesterases, Type 5Diabetic CardiomyopathiesFemaleHumansJNK Mitogen-Activated Protein KinasesMaleMiddle AgedMuscle, SkeletalMyocytes, CardiacNF-kappa BPhosphodiesterase 5 InhibitorsScleroderma, SystemicSildenafil CitrateSTAT1 Transcription FactorChemokine CXCL10CXCL10 protein, humanCyclic Nucleotide Phosphodiesterases, Type 5JNK Mitogen-Activated Protein KinasesNF-kappa BPhosphodiesterase 5 InhibitorsSildenafil CitrateSTAT1 Transcription FactorCXCL10inflammationmyocytessildenafilsystemic sclerosis

Identifiers

PMID33809279
PMCPMC8001273
OpenAlexW3139332728

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.